264 research outputs found
DSBOX: herramienta docente para el diseño y simulación de entornos de red virtualizados
En este trabajo se describe DSBOX, una herramienta gráfica para el diseño y simulación empleando virtualización de pequeñas redes de computadores. Se describe el contexto que ha dado origen a esta herramienta y se detalla su arquitectura y las optimizaciones que se han realizado con el fin de dotar a los alumnos de una herramienta operativa que les facilite la realización de prácticas relacionadas con la seguridad informática y la administración de sistemas. Se presenta también un repositorio de actividades prácticas que hacen uso de la herramienta desarrollada.This paper describes DSBOX, a graphical tool for the design and simulation of small computer networks, employing virtualization software. We describe the context where this tool was created and its architecture and the optimizations that have been made in order to provide our students with a tool giving support to teaching activities in computer security and systems management. Finally, a repository with practical exer-cises using this tool is also described
Acquisition of Advanced Engineered Wood Composites Manufacturing and Science Laboratory
This action is in response to the Major Research Instrumentation Initiative MRI\u2798 (NSF-98-16). The purpose is to upgrade a Composite-Reinforced-Wood (CRW) Manufacturing Science Laboratory at the University of Maine. The laboratory is part of a new facility designed to develop the next generation of wood composites for construction. Recent research has shown that Composite Reinforced Wood (CRW) offers superior properties at reduced costs. As in the development of reinforced and prestressed concrete, basic research is needed to unlock the full potential of a wide variety of CRW structural members, e.g. joists, beams, columns, panel and connections. CRW hybrids are unique in that two very different classes of material, FRP and wood are used together; thus the principles governing the short and long-term structural behavior differ in many ways form those involving only one of the two materials. This project will focus on:Developing a new class of FRP reinforcing materials that are compatible with wood, particularly its hypoexpansion and visco-elastic properties.Developing and maintaining over time the interface (bond) between the two materials needed to ensure full composite action (this will require a basic understanding of the mechanisms of bond durability).Developing a basic understanding of the short and long-term behavior of CRW structural elements including performance over the full range of loading, ultimate strength, ductility, creep, fatigue, and moisture/temperature/UV cycling.The research is conducted at four different levels: micro, meso, macro and structural. A multi-disciplinary team will conduct the research composing ten engineers and scientists from three units at the University of Maine (civil/structural engineering, wood science and technology, and chemical engineering), the industry-supported SPI composites Institute, the Composites Materials Engineering Center (COMTEC) in Winona MN, and the USDA Forest Products laboratory in Madison
Prognostic value of changes in the expression of stem cell markers in the peripheral blood of patients with colon cancer
Cancer stem cells play an important role in carcinogenesis and resistance to treatment and may lead to metastasis. The isolation of circulating stem cells involves cell sorting based on the presence of cell surface markers. Many surface markers such as CD133, c-Kit, SOX, OCT4 and TWIST have been reported. In the present study, we determined the expression of different stem cell markers and their variation in expression at different stages of the treatment process. Samples of EDTA blood were collected from metastatic colorectal cancer patients, and circulating cancer stem cells were isolated for the analysis of the expression of stem cell markers using RT-PCR. These findings were correlated with the response to therapy. All statistical analyses were performed using the GraphPad Prism 5.03 software. Significant differences were found in the expression levels of the markers CD133, SOX2, OCT4 and TWIST1. No differences were found in c-Kit expression. Correlation in the expression levels of most of the markers was observed. Expression of CD133, OCT4, SOX2 and TWIST1 had a predictive value for colon cancer behavior. Evaluation of this stem cell gene expression panel may be useful for predicting the response during the process of treatment, and the relative easy access to samples facilitates this method. Moreover the correlation between CD133 and TWIST1 expression may be associated with tumor regrowth and metastatic relapse
DelfosnetX: A Workbench for XML-based Information Retrieval Systems
Abstract In this paper we present DelfosnetX, an Information Retrieval (IR
Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
Objective: Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT.
Methods: Systematic literature review (SLR), nominal group meeting, and Delphi process. A panel of 12 experts was established who defined the scope, users, and sections of the document. We performed an SLR in order to assess the efficacy and safety of available drugs in patients with mCRPC. Abstracts from the American Society of Oncology and European Society for Medical Oncology meetings were also examined. The results were discussed during an expert meeting in which 14 recommendations were generated. The level of agreement with the recommendations was also tested by 13 additional experts following the Delphi process. Recommendations were voted by means of scores ranging from 0 (total disagreement) to 10 (total agreement). We defined agreement when at least 70% of the experts voted ¿7. Next, we assigned a level of evidence and grade to the recommendation using the Oxford Centre for Evidence-based Medicine Levels of Evidence, following which the final document was drafted. Results: The literature search did not find any articles meeting the inclusion criteria. Finally, 13 out of 14 recommendations were accepted after two Delphi rounds (two were modified after the first round). They pertain to general and individual case-based treatment recommendations.
Conclusions: In mCRPC patients who have progressed after docetaxel or abiraterone plus ADT in the metastatic hormone-sensitive prostate cancer setting, these recommendations may support treatment decision-making, due to the lack of evidence or other globally accepted sequencing algorithms
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial
[Background] There are limited data on toxicity and surgical safety associated with neoadjuvant programmed death ligand 1 (PD-L1) inhibitors prior to radical cystectomy (RC) in patients with muscle-invasive bladder cancer (MIBC).[Objective] To present a comprehensive safety analysis of the largest neoadjuvant series, with focus on timing and severity of toxicity and surgical complications occurring after neoadjuvant atezolizumab in patients with MIBC enrolled in the ABACUS trial.[Design, setting, and participants] ABACUS (NCT02662309) is an open-label, multicenter, phase II trial for patients with histologically confirmed (T2-T4aN0M0) MIBC, awaiting RC. Patients either were ineligible or refused cisplatin-based neoadjuvant chemotherapy.[Intervention] Two cycles of neoadjuvant atezolizumab (1200 mg, every 3 wk) followed by RC.[Outcome measurements and statistical analysis] Description of atezolizumab toxicity profile in the neoadjuvant setting, impact on surgery, and delayed immune-mediated adverse events (AEs) were assessed.[Results and limitations] Ninety-five patients received treatment. Of them, 44% (42/95) had atezolizumab-related AEs during the neoadjuvant period (fatigue [20%], decreased appetite [6%], and transaminases increased [6%]). Treatment-related grade 3–5 AEs occurred in 11% (10/95) of patients during the study. Of the patients, 21% (20/95) received only one cycle of atezolizumab due to AEs; 92% (87/95) underwent RC. No surgery was delayed due to atezolizumab-related toxicities. Surgical complications occurred in 62% (54/87) of patients. Of these patients, 43% (37/87) and 20% (17/87) had minor (grade 1–2) and major (grade 3–5) complications, respectively. Thirteen of 87 (15%) patients had post-RC atezolizumab-related AEs, including adrenal insufficiency and transaminases increased. Three deaths occurred during the period of study-related interventions (one non–treatment-related aspiration pneumonia, one immune-related myocardial infarction, and one cardiogenic shock after RC). Not all surgical safety parameters were available.[Conclusions] Two cycles of neoadjuvant atezolizumab are well tolerated and do not seem to impact surgical complication rates. Owing to the long half-life, AEs may occur in the postoperative period, including endocrine abnormalities requiring attention and intervention.[Patient summary] Here, we report a comprehensive dataset of patients receiving neoadjuvant immune checkpoint inhibitors before radical cystectomy. Treatment with neoadjuvant atezolizumab is safe and does not seem to complicate surgery significantly.Queen Mary University of London was the Sponsor of the study. Roche granted QMUL funding for the study. J. Bull and M. Jacobson also provided financial support for aspects of the biomarker analysis. We acknowledge Cancer Research UK, the UK Experimental Cancer Medicine Network, and La Roche-Hoffmann for funding.Peer reviewe
A Multi-Cancer Mesenchymal Transition Gene Expression Signature Is Associated with Prolonged Time to Recurrence in Glioblastoma
A stage-associated gene expression signature of coordinately expressed genes, including the transcription factor Slug (SNAI2) and other epithelial-mesenchymal transition (EMT) markers has been found present in samples from publicly available gene expression datasets in multiple cancer types, including nonepithelial cancers. The expression levels of the co-expressed genes vary in a continuous and coordinate manner across the samples, ranging from absence of expression to strong co-expression of all genes. These data suggest that tumor cells may pass through an EMT-like process of mesenchymal transition to varying degrees. Here we show that, in glioblastoma multiforme (GBM), this signature is associated with time to recurrence following initial treatment. By analyzing data from The Cancer Genome Atlas (TCGA), we found that GBM patients who responded to therapy and had long time to recurrence had low levels of the signature in their tumor samples (P = 3×10−7). We also found that the signature is strongly correlated in gliomas with the putative stem cell marker CD44, and is highly enriched among the differentially expressed genes in glioblastomas vs. lower grade gliomas. Our results suggest that long delay before tumor recurrence is associated with absence of the mesenchymal transition signature, raising the possibility that inhibiting this transition might improve the durability of therapy in glioma patients
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
Owing to the limited validity of clinical data on the treatment of prostate cancer (PCa) and bone metastases,
biochemical markers are a promising tool for predicting survival, disease progression and skeletal-related events (SREs) in these
patients. The aim of this study was to evaluate the predictive capacity of biochemical markers of bone turnover for mortality risk,
disease progression and SREs in patients with PCa and bone metastases undergoing treatment with zoledronic acid (ZA).
Methods: This was an observational, prospective and multicenter study in which ninety-eight patients were included. Patients
were treated with ZA (4mg every 4 weeks for 18 months). Data were collected at baseline and 3, 6, 9, 12, 15 and 18 months after
the beginning of treatment. Serum levels of bone alkaline phosphtase (BALP), aminoterminal propeptide of procollagen type I
(P1NP) and beta-isomer of carboxiterminal telopeptide of collagen I (b-CTX) were analysed at all points in the study. Data on
disease progression, SREs development and survival were recorded.
Results: Cox regression models with clinical data and bone markers showed that the levels of the three markers studied were
predictive of survival time, with b-CTX being especially powerful, in which a lack of normalisation in visit 1 (3 months after the
beginning of treatment) showed a 6.3-times more risk for death than in normalised patients. Levels of these markers were also
predictive for SREs, although in this case BALP and P1NP proved to be better predictors. We did not find any relationship
between bone markers and disease progression.
Conclusion: In patients with PCa and bone metastases treated with ZA, b-CTX and P1NP can be considered suitable predictors for
mortality risk, while BALP and P1NP are appropriate for SREs. The levels of these biomarkers 3 months after the beginning of
treatment are especially importantThis study was supported by Novartis Oncology Spai
- …